Acerta Pharma Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: San Carlos CA United States (2013)
Status: Acquired by AstraZeneca (2015)

Organization Overview

First Clinical Trial
2014
NCT02029443
First Marketed Drug
2017
acalabrutinib (calquence)
First NDA Approval
2017
acalabrutinib (calquence)
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Acerta Clinical Trials | Acerta Pharma | Acerta Pharma, a member of the AstraZeneca Group | Acerta Pharma BV | Acerta Pharma B.V. | Acerta Pharma, LLC